KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Hologic (HOLX) EBITDA (2016 - 2025)

Hologic's EBITDA history spans 17 years, with the latest figure at $263.3 million for Q4 2025.

  • For Q4 2025, EBITDA rose 4.03% year-over-year to $263.3 million; the TTM value through Dec 2025 reached $747.8 million, down 20.23%, while the annual FY2025 figure was $823.2 million, 16.16% down from the prior year.
  • EBITDA for Q4 2025 was $263.3 million at Hologic, up from $236.9 million in the prior quarter.
  • Across five years, EBITDA topped out at $796.8 million in Q1 2021 and bottomed at -$7.0 million in Q1 2025.
  • The 5-year median for EBITDA is $253.8 million (2024), against an average of $289.3 million.
  • The largest annual shift saw EBITDA surged 17328.57% in 2024 before it crashed 103.33% in 2025.
  • A 5-year view of EBITDA shows it stood at $641.3 million in 2021, then tumbled by 59.08% to $262.4 million in 2022, then fell by 24.47% to $198.2 million in 2023, then grew by 27.7% to $253.1 million in 2024, then rose by 4.03% to $263.3 million in 2025.
  • Per Business Quant, the three most recent readings for HOLX's EBITDA are $263.3 million (Q4 2025), $236.9 million (Q3 2025), and $254.6 million (Q2 2025).